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PSYCHOLOGICAL medicine is today emerging from an isolation born of neglect
and the importance of its contribution to scientific knowledge is becoming
increasingly recognised. More and more emphasis is being laid on its integration
into the field of general medicine and the psychiatrist today is as much a physician
of body as of mind. In no aspect of medicine is this more evident than in the
elder science of neurology where the psychiatrist and physician meet on familiar
ground to study different aspects of the same problems. One of these problems
is the treatment of those patients who suffer from what is commonly called
Parkinsonism, where the mental concomitants include depression which is often
severe and delusional ideas. In a minority of cases the physical symptoms,
especially tremor, can be alleviated by surgery or ultrasonic coagulation, but for
the vast majority treatment depends upon the use of suitable drugs and compounds
such as stramonium, artane and lysivane are commonly employed.
In the last few years attention has been drawn to a new drug called orphen-
adrine, marketed under the trade name of 'Disipal,' which showed great promise
in treating cases of Parkinsonism. Certain special claims have been made for
Disipal, one of which is that it possesses a euphoriant action which helps to relieve
the depression so often associated with Parkinsonism-the so-called psycho-tonic
effect. Chlorpromazine and various drugs of the phenothiazine series can be used
in the treatment of schizophrenia, and in high dosage induce Parkinsonism
symptoms. While the therapeutic value of this is still a very controversial subject,
Disipal can be used to combat their,unwanted side effects.
The aims of the present investigation were:-
1. To ascertain the efficacy of Disipal in controlling the symptoms of Parkinson-
ism: Tremor, rigidity, weakness, salivation, dysarthria and disturbances of
gait.
2. To compare its efficiency with that of other commonly used drugs.
3. To study its effects, if any, on the mental concomitants of Parkinsonism
especially depression.
PHARMACOLOGY.
Disipal is related to diphenhydramine (Benadryl), differing from it by the
substitution of a methyl group. Because of its formula Disipal might be expected
to be an anti-histamine agent like Benadryl, but with the addition of the methyl
64group the anti-histamine action has almost disappeared and has been replaced by
a strong atropine-like effect, i.e., it antagonises acetyl choline. Bijlsma, et al.
(1956), report the acute LD50 dose in rats as 425 mgm. orally or 230 mgm. by
subcutaneous injection.
The synthesis of this drug is a triumph for the research chemists because its
action was predicted accurately by purely theoretical consideration from a
knowledge of molecular structure. However, the actual translation of theory
into reality took seven years and, after physiological assays and toxicity tests on
experimental animals, it was finally handed over for evaluation by clinicians on
suitable cases.
MATERIAL AND METHODS.
Twelve cases of Parkinsonism were selected-six male and six female. All were
in-patients of a modern mental hospital and were under careful observation. The
only criteria of selection were that they should be the worst cases and should
have a marked tremor especially in the upper limbs. Their ages ranged between
41 and 62, and eleven were regarded as being post-encephalitic in origin. Their
stay in hospital varied between four and twenty-nine years. All patients were
nmobile but five required continual assistance with dressing and eating. Their
activities were restricted by their disabilities but most of them were able to walk
for short distances in the immediate vicinity of their wards. Their physical
condition varied only according to the amount of tremor and rigidity present.
Four were subject to frequent and troublesome oculogyric crises. They were
maintained on various combinations mainly of lysivane and stramonium. Two
received lysivane, six lysivane and stramonium, three stramonium and one artane
and stramonium.
Tremor was made one of the criteria because an apparatus was devised with
which it was possible to measure the severity of the tremor with a fair degree
of accuracy. It consists of an electrically-driven drum such as may be found
in any physiology laboratory and which can revolve at different speeds, e.g.,
5 or 11 rev./min. This drum carries a roll of ordinary graph paper and beside
it is a vertical bar. To this bar is clamped at a variable position a strip of very
thin flexible alloy shaped in the form of a right angle like the letter L and
balanced around a small horizontal metal bar which acts as a fulcrum allowing
the L piece to move in a vertical plane. At the tip of the horizontal limb is
attached a tiny cup which serves as an ink reservoir. To the bottom of the
vertical limb is fastened a ring lying in the horizontal plane. The patient places
a finger or thumb in the ring and the tremor is transmitted through the fulcrum
to the horizontal limb, causing a vertical movement of the ink cup and thus
obtaining a tracing on the revolving drum. And so, in the most literal sense,
the moving finger writes.
Every effort was made to standardise the variables involved. Thus the height
of the ring above the table was constant for each patient on each occasion. The
patient was placed at right angles to the apparatus as it was found that this gave
maxinmum amplitude readings of flexion-extension movement which is the chief
65component of Parkinsonian finger tremor. The patients were familiarised with
the apparatus and procedure before commencing. Tracings were taken on three
occasions: -
(1) While on their original drugs.
(2) After all drugs had been withdrawn.
(3) After they had been receiving Disipal for about two months.
PROCEDURE OF TESTS.
Previous medicines were reduced gradually over a period of two-three weeks
until at the end of this time the patients were not receiving any drugs whatsoever
apart from occasional sedation at night. At this stage they all showed marked
deterioration in their general condition as the full effects of the disease made
itself felt. Thev all complained of weakness and objectively there was definite
weakness, increased salivation and lachrymation and difficulty in articulation.
They felt very miserable, lost interest in their former pastimes such as television,
radio or reading, and had great difficulty in walking. Several of them retired to
bed or lay on couches most of the day. A few patients showed increased ex-
citability, became more irritable and noisy and oculogyric crises were more
troublesome in the four cases prone to this disturbance.
Treatment was commenced with Disipal, giving one tablet of 50 mgms.
morning and evening. This was continued for a week and the dosage was then
increased by one tablet of 50 mgms. daily every four or five days. No cases
of drug idiosyncrasy occurred. As dosages were increased two side effects made
their appearance, namely, dizziness and blurred vision, which was reported by
six patients. This occurred at dosage levels of four to seven tablets and dis-
appeared within two days when the dose was reduced. In general the optimum
dosage was found to be four to six tablets per day, i.e., 200-300 mgms.
RESULTS.
It was found that of the twelve patients eleven were restored to the same
condition as while on their previous drugs or improved in various ways. One
patient, a female, was not fully restored although improved in one respect, viz.,
articulation.
Physical symptoms.
The symptoms of the patients after their drugs had been removed have been
described. When Disipal was given and the correct dosage found these symptoms
were all reinedied. Muscular strength was restored and the patients resumed
their former interests and activities. To consider a few of the individual
symptoms:
1. Salivation: This was controlled in all cases.
2. Muscular strength: In eleven cases this was restored to its former level and
apparently increased in three cases because these patients were able to walk
for longer distances and perform tasks for longer periods without becoming
fatigued.
663. Speech: Articulation was improved in four cases and this was noted not
only by the ward staff but by the patients' relatives.
4. Tremor: Studies of the graphs showed that tremor amplitude was reduced
in five cases, was unchanged in six, and was increased in one. There was no
change in tremor frequency and the actual changes noted were seldom
striking.
The above symptoms are all capable of objective study but cannot readily be
expressed in scientific units. All comparisons are drawn with the patient's
condition while on his former drugs.
At this point some sceptic may seek to suggest that all this could conceivably
be psychological, that the improvement was in the mind and not the body. In
order to settle this point identical placebo tablets were substituted to all patients
-the only person who knew about this change being the dispensing chemist.
This, of course, involved the innocent deception of the patients, the nursing
staff and the medical staff in charge of the individual patients who were scattered
throughout the hospital. The substitution was carried out on a Friday and by
the following Monday or Tuesday all the patients were either in bed or on
couches, weak and miserable with increased tremor and salivation. In other
words the syndrome of untreated Parkinsonism had been unleashed again. The
patients were miserable, the nurses were bewildered, and the doctors were
perplexed. One patient interpreted the situation in a typically paranoid fashion
and allegecl that the nurses had poisoned his medicine. The tablets were called
in immediately and genuine Disipal dispensed.
Within two days the situation had changed quite dramatically. Eleven patients
were up and about and were able to resume their former activities. All their
symptoms reverted to their usual base line. The exception to this was the single
female patient mentioned earlier and there was no great change in her condition.
This experience would seem to indicate that the improvement in the patients'
condition was due to the drug and not to any psychological support.
Mental state.
According to their histories only one patient was subject to marked or sustained
depression, the others being liable to patchy depression or changes of mood
such as might be expected in people suffering from the illness. Irritability and
aggression occurred from time to time. One patient had mild paranoid delusions.
When the original drugs were withdrawn ten of the patients became depressed
in some degree, the other two being irritable and aggressive. Insomnia was
marked. When they were stabilised on Disipal this depression disappeared (in
eleven cases) and they all felt in normal spirits again. When placebo was in-
troduced depression again recurred as deep and distressing as before and again
was relieved when Disipal was given.
Depression is sometimes defined as a mood disturbance with a characteristically
sorrowful affect-a somewhat tautological definition. If it is hard to define it
67is even more difficult to measure. There have been various rating scales prepared
with the object of measuring psychomotor activity but they were not considered
to be suitable for the present circumstances. For the purposes of this in-
vestigation, if a patient was lying on a bed or couch apathetic and retarded and
sometimes mentioning suicide with an appropriate affect, he was rated as being
depressed.
DiscusSION.
When receiving Disipal the depression was relieved. This immediately raises
two questions: -
1. Were the patients more cheerful on Disipal than on other drugs?
2. If this is so, is it due to some specific euphoriant effect as claimed by some
investigators?
To give a definite answer to these questions would require an objective
scientific means of measuring small deviations of affect. From the subjective
aspect five patients said that they felt better on Disipal than they had done on
their previous medicines.
The claim that orphenadrine had a specific anti-depressive action was first
advanced by Friesewinkel (1957). An examination of his report, however, shows
that he bases his conclusions on the result of projective techniques. Professor
Eysenck (1959), in his review of personality testing, makes it clear that such
techniques lack validity and are not universally acceptable. Doshay and Constable
(1957) report a euphoriant effect in thirty-one out of thirty-seven patients, while
Robitscher and Pulver (1957) record a similar experience. Fouks, et al. (1959),
noted that many of their patients felt better mentally even though sometimes
they did not display much neurological improvement. A critical scrutiny of these
reports, however, fails to show any series of controls or objective methods to
prove specificity. No one as yet appears to have sought to show that the drug
possesses anti-amine oxidase activity.
It seems more reasonable to suppose that a patient whose physical symptoms
are controlled in a satisfactory manner will feel better as a result of this and to
prove a specific euphoriant effect would require a separate carefully controlled
trial on patients suffering from depression per se quite apart from Parkinsonism.
If, however, a significant proportion of patients feel better on orphenadrine than
oIn other drugs then due notice should be taken of this as a recorded fact and
the accumulated experience of different investigators covering really large
numbers of cases will give a good indication of its value.
The results given here are in general agreement with previous reports. Most
of them, e.g., Berggreen (1958), emphasize the difficulties of accurate evaluation.
Within the limitations outlined earlier it seems justifiable to draw the following
conclusions:
1. Orphenadrine controlled the effects of Parkinsonism in a satisfactory manner
in eleven out of twelve of the patients in this series.
682. Side effects were confined to dizziness and blurred vision and these soon
disappeared when the dosage was reduced. It appears to be a reasonably
safe drug-no toxic effects were noted on kidneys or bone marrow, the
blood picture remaining normal apart from very nild normocytic anaemia
in a few cases. There was no sign of jaundice or liver dainage.
3. The average dose was four to six tablets (200-300 mgms.).
4. As far as could be judged objectively the physical state of the patients in
the majority of cases was at least as good as when they had been receiving
lysivane and stramonium. In four cases an improvement was noted in their
speech-one might say a distinct improvement.
5. The mental state of the patients was satisfactory but a specific euphoriant
effect could not be proved. It was noted that five patients stated that they
preferred Disipal to their previous medicines.
It is obvious that no one drug can be expected to be successful in every case
and that the best one to use is often a matter of experiment. If present trends
continue it seems likely that orphenadrine will establish itself as a standard drug
in the treatnient of Parkinsonism either by itself or in suitable combinations.
SUMMARY.
The symptoms of eleven out of twelve patients suffering from Parkinsonism
with associated mental symptoms were controlled in a satisfactory manner and
improvement was noted in articulation in several cases when compared with their
previous drugs. Side effects were slight and no toxic signs were found. The
mental state was satisfactory and some patients expressed a preference for the
drug. It appears to be as efficacious as other more commonly employed anti-
Parkinson agents.
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